Microbiome Markers of Pancreatic Cancer Based on Bacteria-Derived Extracellular Vesicles Acquired from Blood Samples: A Retrospective Propensity Score Matching AnalysisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared blood microbial extracellular vesicle (EV) profiles between 38 pancreatic cancer patients and 52 healthy controls. The goal was finding candidate biomarkers for earlier pancreatic cancer diagnosis.
How was it studied?
Bacterial EVs were isolated from blood samples and profiled using 16S rRNA gene sequencing. Propensity score matching was applied to reduce confounding before building prediction models from the significant taxa.
What did they find?
At the phylum level, Verrucomicrobia, Deferribacteres, and Bacteroidetes were enriched while Actinobacteria was depleted in cancer patients. At the genus level, Akkermansia, Turicibacter, Ruminiclostridium, and three Lachnospiraceae/Ruminococcaceae-related groups were enriched, while Stenotrophomonas, Sphingomonas, Propionibacterium, and Corynebacterium were depleted. Prediction models built from these markers reached AUC values of 0.966 (phylum) and 1.000 (genus).
Why it matters
Blood bacterial EV composition may offer a minimally invasive route to candidate biomarkers for early pancreatic cancer detection. These findings need validation in larger, independent cohorts before clinical use.